Clinical Trials

Multiple clinical trials sponsored by Eli Lilly and Company evaluated LY2584702 exclusively within Phase 1 development. These early-stage studies investigated the compound as monotherapy or in combination regimens across healthy participants for pharmacokinetic assessment and patients with malignancies including solid tumors, advanced or metastatic cancer, non-small cell lung carcinoma, renal cell carcinoma, and neuroendocrine tumors. Although several trials achieved completed status, others were terminated prior to full completion.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01241461 COMPLETED
Cancer
Eli Lilly and Company
 2010-11 PHASE1
NCT01372085 COMPLETED
Healthy Participants
Eli Lilly and Company
 2011-06 PHASE1
NCT01115803 TERMINATED
Metastases, Neoplasm; Carcinoma, Non-small Cell Lung; Renal Cell Carcinoma; Neuroendocrine Tumors
Eli Lilly and Company
 2010-03 PHASE1
NCT01394003 TERMINATED
Advanced Cancer
Eli Lilly and Company
 2008-11 PHASE1
NCT01241461 Completed
Cancer
Eli Lilly and Company
 2010-11 Phase 1
NCT01115803 Terminated
Metastases Neoplasm|Carcinoma Non-small Cell Lung|Renal Cell Carcinoma|Neuroendocrine Tumors
Eli Lilly and Company
 2010-03 Phase 1
NCT01394003 Terminated
Advanced Cancer
Eli Lilly and Company
 2008-11 Phase 1

(data from https://clinicaltrials.gov, updated on 2018-08-21)

Check the LY2584702 Tosylate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

LY2584702 Tosylate acts as a potent, ATP-competitive inhibitor of p70S6K with an IC50 of 4 nM, directly blocking phosphorylation of downstream ribosomal protein S6 and disrupting mTOR-mediated protein synthesis within target cells. By suppressing ribosomal biogenesis and translation of pro-survival cellular transcripts, this mechanism inhibits tumor cell proliferation and survival, providing therapeutic relevance for clinical evaluation in advanced solid tumors, non-small cell lung carcinoma, renal cell carcinoma, and neuroendocrine malignancies.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.